Combination antifungal therapy for Scedosporium species in cystic fibrosis.

Icon for Wiley Related Articles

Combination antifungal therapy for Scedosporium species in cystic fibrosis.

Pediatr Pulmonol. 2020 Apr 27;:

Authors: Bentley S, Davies JC, Carr SB, Balfour-Lynn IM

Abstract
OBJECTIVE: To evaluate safety and efficacy of oral posaconazole and terbinafine for Lomentospora prolificans and Scedosporium apiospermum in children with cystic fibrosis.
METHODS: Retrospective case review.
RESULTS: There were five children (four girls), median age 15.0 years; three had S. apiospermum and two had L. prolificans. Treatment duration: median 5 months (range: 5-18 m). In no patient was eradication achieved, with the follow-up range being 6 months to 4 years. Effect on lung function was variable but encouraging. No adverse effects were reported, one child had transient elevation of liver enzymes.
CONCLUSIONS: While the combination therapy was well tolerated, it was unsuccessful at eradication.

PMID: 32339450 [PubMed - as supplied by publisher]